Wellgistics Health, Inc. Terminates Settlement Agreement with Silverback Capital Inc.; Pursues New Strategic and Financing Initiatives

Key Highlights for Investors

• Termination of Settlement Agreement: Wellgistics Health, Inc. (“the Company”) has delivered written notice to Silverback Capital Inc. to terminate the Settlement Agreement and Stipulation originally entered on January 28, 2026.
• Reason for Termination: The Company is choosing to pursue alternative strategic and financing initiatives, moving away from the previously disclosed settlement structure.
• Potential Impact on Shareholders: The termination eliminates the potential for future dilution associated with the Settlement Agreement, a development that could positively influence the share value.
• Details of Prior Issuance: Before this termination, the Company had issued a total of 6,866,000 shares of common stock under the Settlement Agreement, relying on Section 3(a)(10) of the Securities Act of 1933, as amended.
• No Further Share Issuance: Following the termination, no additional shares will be issued under the Settlement Agreement or in reliance on Section 3(a)(10).
• Return of Unpaid Claims: Silverback Capital Inc. has been requested by Wellgistics Health, Inc. to return all rights, title, and interest in and to any unpaid claims to the appropriate creditors.
• No Further Obligations: Both Wellgistics Health, Inc. and Silverback Capital Inc. have no further obligations under the Settlement Agreement.
• Emerging Growth Company: Wellgistics Health, Inc. remains an emerging growth company listed on NASDAQ under the ticker symbol WGRX.

What Shareholders Need to Know

The Company’s decision to terminate the Settlement Agreement and to pursue alternative financing and strategic options is a significant development. The prior agreement had resulted in the issuance of over 6.8 million shares, which may have contributed to dilution of existing shareholders’ equity. By halting further share issuances under this agreement, the Company is effectively addressing a key concern regarding potential future dilution.

Additionally, the Company’s announcement that it is seeking new strategic and financing alternatives may signal upcoming initiatives that could impact the business direction and valuation. The elimination of obligations tied to the Settlement Agreement could free up resources and flexibility for Wellgistics Health, Inc. to negotiate or enter into potentially more favorable arrangements.

Importantly, the return of any unpaid creditor claims by Silverback Capital Inc. may further clarify and strengthen the Company’s financial position, removing lingering uncertainties related to the prior settlement structure.

Potential Price Sensitivity

• This development removes the immediate risk of further dilution, which is typically viewed positively by the market and could result in upwards price movement for WGRX shares.
• The Company’s intent to seek alternative financing and strategic initiatives introduces the potential for future corporate actions, partnerships, or capital raises—each of which could materially impact shareholder value depending on their structure and outcome.

Summary Table

Conclusion

The termination of the Settlement Agreement with Silverback Capital Inc. and the Company’s shift toward new strategic and financing initiatives is a potentially price-moving development for Wellgistics Health, Inc. shareholders. The removal of dilution risk and the prospect of new strategic directions warrant close monitoring for future announcements.

Disclaimer: This article is based on the Company’s public SEC filing as of April 2026. It is not investment advice. Investors should conduct their own due diligence and consult their financial advisor before making any investment decisions. The information may be subject to change and may not reflect subsequent events or filings.

View Wellgistics Health, Inc. Historical chart here